review · Molecules
Treating chronic conditions such as cancer and evolving infectious diseases has become increasingly difficult due to mutations, dynamic pathogens, and resulting drug resistance mechanisms. Because synthesising entirely new medications involves immense financial costs, attention has turned towards innovative drug delivery systems. Nanotechnology offers significant opportunities to improve existing therapeutics. At the preclinical stage, nanomedicine formulations demonstrate greater efficacy and diminished toxicity compared to conventional approaches. Nevertheless, major bottlenecks hinder the translation of these laboratory successes into routine clinical practice. Critical hurdles include regulatory approval, manufacturing scalability, high production costs, and potential toxic side effects. Overcoming these barriers requires dedicated research funding alongside streamlined regulatory procedures. By addressing these practical and clinical challenges, nanoscale drug delivery systems could help revitalise treatment strategies, transforming research outcomes into tangible clinical benefits for patients facing treatment-resistant infections and malignant cancers.
Drug resistance causes therapies for cancer and infectious diseases to fail, while creating new pharmaceuticals is costly and slow. Using nanotechnology to deliver existing medicines offers a way to enhance efficacy and lessen harmful side effects. Addressing translational challenges such as regulation, safety, and manufacturing scale is crucial for bringing these promising therapeutic delivery methods to patients who urgently need effective treatment options.
The applications focus on advanced therapeutic delivery formulations for pharmaceutical developers targeting drug-resistant cancers and infections. The technology remains largely in early-stage preclinical development. Commercial translation faces significant bottlenecks, specifically regarding manufacturing scalability, high production costs, potential toxicity, and complex regulatory approval pathways. Broad market entry will depend on resolving these operational hurdles and securing targeted funding to bridge the gap between laboratory research and clinical adoption.
AI-generated from the published abstract. Always read the original work before citing.
There is a myriad of diseases that plague the world ranging from infectious, cancer and other chronic diseases with varying interventions. However, the dynamism of causative agents of infectious diseases and incessant mutations accompanying other forms of chronic diseases like cancer, have worsened the treatment outcomes. These factors often lead to treatment failure via different drug resistance mechanisms. More so, the cost of developing newer drugs is huge. This underscores the need for a paradigm shift in the drug delivery approach in order to achieve desired treatment outcomes. There is intensified research in nanomedicine, which has shown promises in improving the therapeutic outcome of drugs at preclinical stages with increased efficacy and reduced toxicity. Regardless of the huge benefits of nanotechnology in drug delivery, challenges such as regulatory approval, scalability, cost implication and potential toxicity must be addressed via streamlining of regulatory hurdles and increased research funding. In conclusion, the idea of nanotechnology in drug delivery holds immense promise for optimizing therapeutic outcomes. This work presents opportunities to revolutionize treatment strategies, providing expert opinions on translating the huge amount of research in nanomedicine into clinical benefits for patients with resistant infections and cancer.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/molecules29112584
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
